Some high-cost specialty drugs reach patients only through a limited distribution drug network, a dispensing channel the manufacturer controls rather than the patient's pharmacy. A specialty pharmacy left out of that network has no authorized channel to dispense the product. Exclusion can end a significant revenue line, and filling the same drug from outside the authorized channel creates PBM audit and recoupment exposure on top of it.
What Makes a Drug a Limited Distribution Drug
A limited distribution drug is a manufacturer's own commercial designation: a decision to route dispensing through a defined, contracted network of pharmacies rather than the open market, a term the FDA's governing statute on risk management does not define or use. A drug subject to an FDA Risk Evaluation and Mitigation Strategy (REMS) can include Elements to Assure Safe Use under 21 U.S.C. Section 355-1(f)(3), letting the FDA require that a dispensing pharmacy be specially certified. A new product launch may instead concentrate early dispensing in pharmacies able to collect clinical data, or a high-cost therapy may require handling the manufacturer wants confined to a known set of pharmacies. A manufacturer can impose the restriction through contract alone, without any REMS requirement.
Who Decides Pharmacy Access
The manufacturer, or a distribution agent acting on its behalf, decides which pharmacies join the network and sets the terms of participation, a decision that sits outside the PBM claims-adjudication relationship. A pharmacy can be fully credentialed with every PBM that covers the drug and still be unable to dispense it, because PBM network status governs claim payment, not physical access to the product. A finding in either system can still affect the pharmacy's standing in the other.
The Criteria Manufacturers Commonly Apply
Criteria vary by manufacturer and product, and no single published standard governs every network. Published descriptions of these arrangements cite national specialty-pharmacy credentials, including ACHC accreditation, clinical monitoring and patient adherence programs for the relevant disease state, and the data-reporting and patient-monitoring systems that a drug's REMS can require. A pharmacy seeking access applies directly to the manufacturer or its distribution agent, since no government application process exists.
A specialty pharmacy excluded from a drug's limited distribution network has no authorized channel to obtain that drug, and sourcing it from another wholesaler or pharmacy to fill a patient's prescription creates audit and recoupment exposure.
The Audit Risk of Filling Outside the Authorized Channel
A pharmacy that is not in the network but fills the prescription anyway, by sourcing the product through a secondary wholesaler or a transferring pharmacy, creates exposure on two fronts. The claim can trigger a PBM audit once the payor's system flags a national drug code dispensed outside the manufacturer's authorized list, and a finding can lead to a recoupment demand across the lookback period. A pharmacy disputing the finding can still pursue an audit appeal, which addresses the claim-payment dispute. Network access remains the manufacturer's separate decision, and in serious cases the PBM audit can escalate from recoupment into network termination.
The exposure compounds for pharmacies that ship the drug, an area Mail Order Versus Retail: Why PBMs Audit Shipped Prescriptions covers in more depth, and for groups operating across several locations, where Multi-Location Pharmacy Groups: Audit Exposure Across Stores can turn one store's unauthorized fills into a finding against the whole group.
Challenging an Exclusion: An Open Question
Pharmacies excluded from a limited distribution network have looked for a legal theory that would compel admission, and none has produced a settled, general right of access. Medicare Part D's any-willing-pharmacy standard, codified at 42 U.S.C. Section 1395w-104(b)(1)(A), requires a Part D plan sponsor to admit any pharmacy accepting the plan's standard terms, but that provision governs a plan's claims network, not a manufacturer's distribution channel, and no court has extended it to a manufacturer's network decision.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a network exclusion notice, a REMS compliance inquiry, or a PBM audit letter tied to limited distribution dispensing. Early legal intervention can protect the pharmacy's contractual rights, support an accurate response to the manufacturer's or the PBM's documentation requests, and preserve the pharmacy's audit appeal options. Delaying representation can affect the outcome on either track.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Health Law Alliance represents specialty and independent pharmacies on both tracks a limited distribution dispute can take: the manufacturer-side network relationship and the PBM audit that can follow from it. If your pharmacy has received a network exclusion notice or a PBM audit letter involving a limited distribution drug, contact Health Law Alliance's PBM audit defense attorneys for a free, confidential consultation.
